Literature DB >> 1835289

The influence of anticholinergic agents on treatment for bronchitis and emphysema.

N J Gross1.   

Abstract

Recent studies have shown that anticholinergic therapy is more effective than the most potent beta-adrenergic agents for chronic obstructive pulmonary disease. In the 3 years since it has been available to physicians in the United States, the quaternary anticholinergic drug ipratropium bromide (Atrovent) has had a considerable influence on clinical practice and the management of patients who have this disease. However, knowledge in this area is still incomplete. Questions remain as to the long-term effects of anticholinergic agents on the airways and, perhaps more important, on the natural progression of chronic obstructive pulmonary disease. Studies currently in progress will help determine the effect of prolonged therapy with anticholinergic agents on the progression and morbidity of lung disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1835289     DOI: 10.1016/0002-9343(91)90255-v

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  5 in total

1.  Cor Pulmonale.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

Review 2.  Overcoming gaps in the management of asthma in older patients: new insights.

Authors:  Pranoy Barua; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Physiological changes due to age. Implications for respiratory drug therapy.

Authors:  J F Morris
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

4.  Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis.

Authors:  J Tamaoki; A Chiyotani; E Tagaya; N Sakai; K Konno
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

Review 5.  Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment.

Authors:  Ondrej Soukup; Michael Winder; Uday Kumar Killi; Vladimir Wsol; Daniel Jun; Kamil Kuca; Gunnar Tobin
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.